242 related articles for article (PubMed ID: 27194387)
21. An anti-IgE monoclonal antibody that binds to IgE on CD23 but not on high-affinity IgE.Fc receptors.
Shiung YY; Chiang CY; Chen JB; Wu PC; Hung AF; Lu DC; Pan RL; Chang TW
Immunobiology; 2012 Jul; 217(7):676-83. PubMed ID: 22226669
[TBL] [Abstract][Full Text] [Related]
22. Effects of omalizumab on basophils: Potential biomarkers in asthma and chronic spontaneous urticaria.
Poddighe D; Vangelista L
Cell Immunol; 2020 Dec; 358():104215. PubMed ID: 33137647
[TBL] [Abstract][Full Text] [Related]
23. Structural basis for selective inhibition of immunoglobulin E-receptor interactions by an anti-IgE antibody.
Chen JB; Ramadani F; Pang MOY; Beavil RL; Holdom MD; Mitropoulou AN; Beavil AJ; Gould HJ; Chang TW; Sutton BJ; McDonnell JM; Davies AM
Sci Rep; 2018 Aug; 8(1):11548. PubMed ID: 30069035
[TBL] [Abstract][Full Text] [Related]
24. Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin.
Metz M; Staubach P; Bauer A; Brehler R; Gericke J; Kangas M; Ashton-Chess J; Jarvis P; Georgiou P; Canvin J; Hillenbrand R; Erpenbeck VJ; Maurer M
Theranostics; 2017; 7(5):1266-1276. PubMed ID: 28435464
[No Abstract] [Full Text] [Related]
25. Accelerated disassembly of IgE-receptor complexes by a disruptive macromolecular inhibitor.
Kim B; Eggel A; Tarchevskaya SS; Vogel M; Prinz H; Jardetzky TS
Nature; 2012 Nov; 491(7425):613-7. PubMed ID: 23103871
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of human cord blood-derived mast cell responses by anti-Fc epsilon RI mAb 15/1 versus anti-IgE Omalizumab.
Mirkina I; Schweighoffer T; Kricek F
Immunol Lett; 2007 Apr; 109(2):120-8. PubMed ID: 17368811
[TBL] [Abstract][Full Text] [Related]
27. The discovery and development of omalizumab for the treatment of asthma.
Licari A; Marseglia G; Castagnoli R; Marseglia A; Ciprandi G
Expert Opin Drug Discov; 2015; 10(9):1033-42. PubMed ID: 25979110
[TBL] [Abstract][Full Text] [Related]
28. Approaches to target IgE antibodies in allergic diseases.
Balbino B; Conde E; Marichal T; Starkl P; Reber LL
Pharmacol Ther; 2018 Nov; 191():50-64. PubMed ID: 29909239
[TBL] [Abstract][Full Text] [Related]
29. Directed evolution of and structural insights into antibody-mediated disruption of a stable receptor-ligand complex.
Pennington LF; Gasser P; Kleinboelting S; Zhang C; Skiniotis G; Eggel A; Jardetzky TS
Nat Commun; 2021 Dec; 12(1):7069. PubMed ID: 34862384
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of ongoing allergic reactions using a novel anti-IgE DARPin-Fc fusion protein.
Eggel A; Buschor P; Baumann MJ; Amstutz P; Stadler BM; Vogel M
Allergy; 2011 Jul; 66(7):961-8. PubMed ID: 21272035
[TBL] [Abstract][Full Text] [Related]
31. An immunoglobulin E-reactive chimeric human immunoglobulin G1 anti-idiotype inhibits basophil degranulation through cross-linking of FcepsilonRI with FcgammaRIIb.
Wigginton SJ; Furtado PB; Armour KL; Clark MR; Robins A; Emara M; Ghaemmaghami AM; Sewell HF; Shakib F
Clin Exp Allergy; 2008 Feb; 38(2):313-9. PubMed ID: 18070161
[TBL] [Abstract][Full Text] [Related]
32. Treatment of chronic autoimmune urticaria with omalizumab.
Kaplan AP; Joseph K; Maykut RJ; Geba GP; Zeldin RK
J Allergy Clin Immunol; 2008 Sep; 122(3):569-73. PubMed ID: 18774392
[TBL] [Abstract][Full Text] [Related]
33. Structure of intact IgE and the mechanism of ligelizumab revealed by electron microscopy.
Jensen RK; Jabs F; Miehe M; Mølgaard B; Pfützner W; Möbs C; Spillner E; Andersen GR
Allergy; 2020 Aug; 75(8):1956-1965. PubMed ID: 32037590
[TBL] [Abstract][Full Text] [Related]
34. In vitro basophil activation is reduced by short-term omalizumab treatment in hydrolyzed wheat protein allergy.
Chinuki Y; Yagami A; Adachi A; Matsunaga K; Ugajin T; Yokozeki H; Hayashi M; Katayama I; Kohno K; Shiwaku K; Morita E
Allergol Int; 2020 Apr; 69(2):284-286. PubMed ID: 31753713
[No Abstract] [Full Text] [Related]
35. Omalizumab does not lead to a distinct alteration in hematological parameters and complete blood count-derived inflammation biomarkers except for basophil count.
Tamer F
Cutan Ocul Toxicol; 2020 Sep; 39(3):229-232. PubMed ID: 32380865
[TBL] [Abstract][Full Text] [Related]
36. Novel 2-(substituted phenyl)benzimidazole derivatives with potent activity against IgE, cytokines, and CD23 for the treatment of allergy and asthma.
Richards ML; Lio SC; Sinha A; Tieu KK; Sircar JC
J Med Chem; 2004 Dec; 47(26):6451-4. PubMed ID: 15588078
[TBL] [Abstract][Full Text] [Related]
37. Structure/function studies on IgE as a basis for the development of rational IgE antagonists.
Helm BA; Sayers I; Padlan EA; McKendrick JE; Spivey AC
Allergy; 1998; 53(45 Suppl):77-82. PubMed ID: 9788713
[No Abstract] [Full Text] [Related]
38. Participation of the N-terminal region of Cepsilon3 in the binding of human IgE to its high-affinity receptor FcepsilonRI.
Henry AJ; Cook JP; McDonnell JM; Mackay GA; Shi J; Sutton BJ; Gould HJ
Biochemistry; 1997 Dec; 36(50):15568-78. PubMed ID: 9398285
[TBL] [Abstract][Full Text] [Related]
39. Immunological methods for quantifying free and total serum IgE levels in allergy patients receiving omalizumab (Xolair) therapy.
Hamilton RG; Marcotte GV; Saini SS
J Immunol Methods; 2005 Aug; 303(1-2):81-91. PubMed ID: 16045925
[TBL] [Abstract][Full Text] [Related]
40. IgE-Related Chronic Diseases and Anti-IgE-Based Treatments.
Navinés-Ferrer A; Serrano-Candelas E; Molina-Molina GJ; Martín M
J Immunol Res; 2016; 2016():8163803. PubMed ID: 28097159
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
